EXOZYMES INC
EXOZNASDAQTrading Snapshot
- Day Range
- $2.84 β $3.31
- 52-Week Range
- $2.81 β $16.48
- Volume (shares)
- 10,823
- Avg Volume (shares)
- β
- Shares Outstanding
- 9.4M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -2.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.09
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.1%
EXOZYMES INC
EXOZAbout EXOZYMES INC
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research
October 22 investor event will explore eXoZymes' commercialization, manufacturing economics, path to market launch, growth strategy, and milestones ahead. LOS ANGELES, CA / ACCESS Newswire / October 21, 2026 / Today, eXo

Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
October 2, 2026, ST. PETERSBURG, FL β Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, βConverting Cell-Free Science into a Scalabl

Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)
Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of A

eXoZymes Q2 Earnings Call Highlights
eXoZymes (NASDAQ: EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select